1.09
-0.04 (-3.54%)
|
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| C Worldwide Group Holding A/S | 31 Dec 2023 | 1,500,000 |
| 52 Weeks Range |
0.617 - 3.87
|
|
| High | 8.00 (HC Wainwright & Co., 633.94%) | Buy |
| Median | 8.00 (633.94%) | |
| Average | 8.00 (633.94%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 01 Mar 2024 | 8.00 (633.94%) | Buy | 1.19 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| RANGWALA RESHMA | - | 1.13 | -6,789 | -7,672 |
| Aggregate Net Quantity | -6,789 | |||
| Aggregate Net Value ($) | -7,672 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 1.13 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| RANGWALA RESHMA | Officer | 22 Apr 2024 | Sell (-) | 6,789 | 1.13 | 7,672 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |